
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. is poised for significant growth due to its advanced Enhanced Delivery Oligonucleotide platform, which has demonstrated superior tissue penetration and cellular uptake in preclinical studies. The company's lead asset, PGN-EDO51, has shown a remarkable 53.7% splicing correction, surpassing competitors and indicating strong potential for measurable improvements in muscle performance in upcoming clinical trials. As shares trade around ~$4, the analysis suggests meaningful upside potential contingent on positive multi-dose data outcomes, highlighting optimism surrounding the company's innovative pipeline and efficacy results.
Bears say
The financial outlook for PepGen Inc. appears negative due to a recent model update indicating a decrease in the projected stock target by $1 to $8 per share. The company's positioning, despite delivering promising data for its DM1 treatment, reflects a substantial market cap discount compared to competitors like Dyne, which raises concerns regarding execution and the ability to meet stakeholder expectations. Additionally, potential challenges in accessing capital markets could hinder development efforts, leading to possible delays or termination of key projects, further negatively impacting investor sentiment.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares